Recruitment

Recruitment Status
Not yet recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Parotid Tumor
  • Thymus Cancer
  • Osteosarcoma
  • Sarcoma
  • Cancer of Pancreas
  • Pheochromocytoma
  • Liposarcoma
  • Head and Neck Neoplasms
  • Adenocarcinoma
  • Adenocystic Carcinoma
  • Chondrosarcoma
  • Rectal Cancer
  • Stomach Cancer
  • Ovarian Cancer
  • Cervical Cancer
  • Fallopian Tube Cancer
  • Melanoma
  • Adrenal Cancer
  • Pancreatic Cancer
  • Hepatic Cancer
  • Kidney Cancer
  • Brain Tumor
  • Breast Cancer
  • Gestational Trophoblastic Tumor
  • Multiple Endocrine Neoplasia
  • Vulvar Cancer
  • Waldenstrom Macroglobulinemia
  • Small Cell Carcinoma
  • Anal Cancer
  • Nasopharyngeal Carcinoma
  • Testicular Cancer
  • Renal Cell Carcinoma
  • Chronic Myeloid Leukemia
  • Unknown Primary Tumors
  • Skin Cancer
  • Brain Stem Neoplasms
  • Carcinoid Tumor
  • Esophageal Cancer
  • Appendix Cancer
  • Astrocytoma
  • Glioblastoma
  • Cholangiocarcinoma
  • Cancer, Advanced
  • Bile Duct Cancer
  • Sarcoma, Kaposi
  • Synovial Sarcoma
  • Multiple Myeloma
  • Vaginal Cancer
  • Esophagus Cancer
  • Larynx Cancer
  • Lung Cancer
  • Pulmonary Carcinoma
  • Salivary Gland Cancer
  • Neuroendocrine Tumors
  • Testis Cancer
  • Thyroid Cancer
  • Mesothelioma
  • Bladder Cancer
  • Liver Cancer
  • Pharynx Cancer
  • Uterine Cancer
  • Colorectal Cancer
  • Small Bowel Cancer
  • Non Hodgkin Lymphoma
  • Parathyroid Neoplasms
  • Sarcoma,Soft Tissue
  • CNS Cancer
  • Ureter Cancer
  • Penile Cancer
  • Prostate Cancer
  • Tongue Cancer
  • Colon Cancer
  • Cancer of Colon
  • Bone Cancer
Design
Observational Model: CohortTime Perspective: Prospective

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

This is a master observational trial (MOT). Anyone who has been diagnosed with advanced cancer is eligible as long as they are a candidate for treatment. Each patient will receive testing and treatment as determined by patient in consultation with physician. ROOT will proceed in two directions: (1) ...

This is a master observational trial (MOT). Anyone who has been diagnosed with advanced cancer is eligible as long as they are a candidate for treatment. Each patient will receive testing and treatment as determined by patient in consultation with physician. ROOT will proceed in two directions: (1) Validation Cohorts. These patients will demonstrate the ability of the MOT to prospectively collect data using the same protocol and related documents, standardized data elements and processes, and accepted scientific endpoints; and (2) Analysis Cohorts. The modular nature of the study allows collection of RWD ranging from diagnosis only to the full treatment course of the of the patient. Patients are grouped to allow focused data collection or a specific analysis. Analysis cohorts can be created from patients already enrolled in ROOT or be defined prospectively. Because of the ongoing advancements of molecular based oncology, this trial allows a detailed focus on molecular testing as part of any cohort. Data is reported by the group that is most qualified to provide this information and is proved, at point of care, using standardized data elements and processes. Physicians will report diagnosis, molecular characteristics, staging, disease burden, significant comorbidities, treatment response, and medical decision making. Molecular testing (reports and details) will be requested from testing laboratories. Any diagnostic films will be received digitally from the location the study was performed. Research staff assist in data entry and providing physicians needed data as part of the regular workflow to allow point-of-care reporting. The Validation Cohorts and Analysis Cohorts may run sequentially or in parallel with each other.

Tracking Information

NCT #
NCT04028479
Collaborators
Not Provided
Investigators
Study Chair: Razelle Kurzrock, MD Moores Cancer Center at University of California at San Diego Principal Investigator: Vivek Subbiah, MD M.D. Anderson Cancer Center Principal Investigator: Jennifer Johnson, MD, PhD Sidney Kimmel Cancer Center at Thomas Jefferson University Principal Investigator: Raymond Bergan, MD OHSU Knight Cancer Institute